Holen Sie sich die Stockscreener-App
41.49
0.29%
-0.0139
Schlusskurs vom Vortag:
$41.48
Offen:
$41.39
24-Stunden-Volumen:
2.43M
Relative Volume:
0.38
Marktkapitalisierung:
$30.01B
Einnahmen:
$8.26M
Nettoeinkommen (Verlust:
$-397.91M
KGV:
-82.39
EPS:
-0.5036
Netto-Cashflow:
$-758.56M
1W Leistung:
+21.00%
1M Leistung:
+13.81%
6M Leistung:
+40.06%
1J Leistung:
+206.82%
1-Tages-Spanne:
$41.08
$41.98
1-Wochen-Bereich:
$33.67
$42.50
52-Wochen-Spanne:
$13.39
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
41.54 | 29.96B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.39 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.59 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Outperform |
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
H.C. Wainwright raises Roivant Sciences price target on trial data - Investing.com
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41% - Yahoo Finance
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com Australia
Biotech Trial Wins Sent Roivant And Pharvaris Higher - Finimize
ROIV Looks 472.1% Overvalued on GF Value™ Amid Clinical Trial Su - GuruFocus
Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $47 - GuruFocus
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Yahoo Finance
Roivant shares jump 17% as lung disease drug meets trial goals - Investing.com Canada
Roivant Sciences Surges 17.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com South Africa
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - Barron's
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
Roivant at Wells Fargo conference: pipeline momentum lifts outlook By Investing.com - Investing.com Canada
Transcript : Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM - marketscreener.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings - Benzinga
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Roivant Shares Surge as Mosliciguat Hits Primary Endpoint in Phase 2 PH-ILD Study - Minichart
Roivant's experimental lung disease drug meets goals in mid-stage study - Reuters
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - Quiver Quantitative
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data - BioSpace
Roivant Sciences stock surges on positive PH-ILD trial data - Investing.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Roivant Sciences stock hits all-time high at 39.99 USD By Investing.com - Investing.com Canada
Roivant Sciences stock hits all-time high at 39.99 USD - Investing.com
ROIV: Mosliciguat delivered unprecedented PVR reduction and functional gains in PH-ILD, with strong safety - TradingView
Up to 200,000 PH-ILD patients lack options as Roivant (NASDAQ: ROIV) moves mosliciguat into a Phase 3 trial - Stock Titan
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate - Yahoo Finance
ROIV Looks 381.9% Overvalued on GF Value™ - GuruFocus
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director - GlobeNewswire Inc.
Roivant reports mosliciguat Phase 2 PH-ILD results - grafa.com
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High - Yahoo Finance
Why Is ROIV Stock Tracking Record Highs In Pre-Market Today? - Stocktwits
S&P 500 Futures Decline in Premarket Trading; Roivant Sciences, Bloom Energy Lead - Barron's
Roivant stock climbs on mid-stage trial win (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results - Yahoo Finance
Roivant reports positive phase 2 trial results for mosliciguat By Investing.com - Investing.com Nigeria
Why is Roivant Sciences stock surging today? - Investing.com
Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD - insights.citeline.com
Up to 200,000 people live with this lung disease. Roivant starts a new trial. - Stock Titan
What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV) - Yahoo! Finance Canada
Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity? - Yahoo! Finance Canada
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring A 20% Upside In The Biotech Sphere - DirectorsTalk Interviews
Roivant to present phase 2 pulmonary hypertension study results By Investing.com - Investing.com Australia
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Aug 28 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Venker Eric | President & Immunovant CEO |
Aug 28 '26 |
Sale |
35.77 |
200,000 |
7,153,393 |
1,599,154 |
3.49%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):